Open Label Trial of Aripiprazole in Trichotillomania.

No medication has been reliably shown to benefit those suffering from trichotillomania (compulsive hair pulling). The current study proposes to evaluate the effectiveness of the medication aripiprazole for treatment of trichotillomania (TTM). Patients will take a gradually increased dose of the medication in an open-label study to see whether it relieves hair-pulling urges, decreases hair pulling behavior and is well tolerated.

Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.

Investigator(s):

Intervention(s):

  • drug : aripiprazole

Phase: N/A

Eligibility

Ages Eligible For Study:

18 Years - 65 Years

Inclusion Criteria

Eligible patients: - Must be outpatients between the ages of 18 and 65 at the start of study - May be male or female - Have DSM-IV trichotillomania of at least 6 months duration - Allowed psychotropic medications are limited to: - SSRIs (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline), SNRIs (duloxetine, venlafaxine) and mirtazapine, as long as the dosage has not changed for 4 weeks prior to study enrollment. - Other allowed medications include non-hypnotic sleeping agents, specifically trazodone, diphenhydramine, hydoxyzine and ramelteon. - If a patient is taking non-allowed psychotropic medications, he/she must be titrated off by the prescribing physician and be off of the medication for at least 2 weeks prior to trial enrollment. - We will not exclude patients meeting DSM-IV criteria for: - body dysmorphic disorder; - major depression; - dysthymia; - GAD, social phobia, panic disorder.

External Links

Contact information

Primary Contact:

Matthew White 6507255598

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: